Tal Zaks
November 1, 2021 10:52 AM EDT
People

Tal Zak­s' post-Mod­er­na fu­ture is now in view as he joins biotech VC blue-chip­per Or­biMed

Nicole DeFeudis

Editor

It’s hard to imag­ine what comes next for a physi­cian-sci­en­tist who’s de­vel­oped one of the most lu­cra­tive vac­cines in bio­phar­ma his­to­ry. On Mon­day — a month …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times